You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo
since
auto-detected in 124 stories
2 days ago
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
3 days ago
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients ⊖
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
4 days ago
Novo Nordisk shares drop 10% after poor weight loss trial result ⊖⊖
Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial ⊖
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
15 days ago
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start ⊕
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
16 days ago
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs ⊕
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.
17 days ago
Wegovy maker sues rival over 'knock-off' weight-loss drugs ⊖
Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".
The race for cheaper GLP-1 drugs is hitting legal limits ⊖
found
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and ris…
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims ⊖⊖
The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.